Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ReNeuron Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ReNeuron Group Plc, Medical Devices Deals, 2012 to YTD 2018 10
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
ReNeuron Enters into Research Agreement with Benitec Biopharma 12
ReNeuron Enters Into Co-Development Agreement With Cell Therapy Catapult 13
Licensing Agreements 14
ReNeuron Enters into Licensing Agreement with US-Based Pharma Company 14
Equity Offering 15
ReNeuron Raises USD105 Million in Private Placement of Shares 15
ReNeuron Raises USD25.4 Million in Private Placement of Shares 16
ReNeuron Group Completes Private Placement Of Shares For US$8.7 Million 17
ReNeuron Group Completes Rights Offering Of Shares For US$1 Million 19
ReNeuron Group Plc – Key Competitors 21
ReNeuron Group Plc – Key Employees 22
ReNeuron Group Plc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Jul 12, 2018: ReNeuron: Preliminary results for the year ended 31 March 2018 24
Dec 14, 2017: ReNeuron Group: Interim Results for the six months ended 30 September 2017 30
Jun 29, 2017: ReNeuron Group: Preliminary Results for the Year Ended 31 March 2017 33
Corporate Communications 34
Apr 10, 2018: ReNeuron: Appointment of US-based Chief Medical Officer 34
Apr 10, 2018: Appointment Of US-Based Chief Medical Officer 35
Sep 01, 2017: ReNeuron Group: Non-executive Director Appointment 36
Jul 19, 2017: ReNeuron Group: Board change 37
Government and Public Interest 38
Apr 19, 2018: ReNeuron: Wins grant for retinal cell therapy development 38
May 11, 2017: ReNeuron awarded major UK cell therapy manufacturing grant 39
Jan 23, 2017: Merck Announces Emerging Biotech Grant Program Winners 40
Product News 41
11/08/2017: ReNeuron Group: Retinal disease clinical trial moves into Phase II 41
06/19/2017: FDA approves cryopreserved formulation of ReNeurons retinal stem cell therapy candidate 42
05/05/2017: ReNeuron presents new data with its exosome therapy programme at major scientific conference 43
04/19/2018: ReNeuron wins grant for retinal cell therapy development 44
Mar 26, 2018: ReNeuron Group: Product Development Update 45
Clinical Trials 47
May 04, 2018: ReNeuron Group: Exosome data presented at ISCT conference 47
Feb 13, 2018: ReNeuron Group: Positive pre-clinical data in nerve injury 48
Jan 26, 2018: ReNeuron: Phase II stroke data presented at AHA conference 49
Dec 14, 2017: ReNeuron Group: Stroke Clinical Trial Regulatory Approval in US 50
Oct 31, 2017: ReNeuron Group: Positive stroke clinical data & regulatory update 51
Oct 09, 2017: ReNeuron presents positive pre-clinical data with its ExoPr0 exosome cancer therapy candidate at American Society for Exosomes and Microvesicles 2017 Annual Meeting 52
Jun 05, 2017: ReNeuron progresses clinical and regulatory strategy for the US with stroke programme based on positive FDA regulatory feedback 53
May 18, 2017: ReNeuron presents positive pre-clinical data with its ExoPr0 exosome therapy candidate at major scientific conference 54
Apr 21, 2017: ReNeuron advances global clinical development strategy with cell therapy candidate for stroke disability 55
Other Significant Developments 56
Sep 19, 2018: ReNeuron Group provides business development update 56
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 57
Apr 21, 2017: ReNeuron successfully develops cryopreserved formulation of its retinal stem cell therapy candidate and expands ophthalmology programmes 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ReNeuron Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ReNeuron Group Plc, Deals By Therapy Area, 2012 to YTD 2018 9
ReNeuron Group Plc, Medical Devices Deals, 2012 to YTD 2018 10
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ReNeuron Enters into Research Agreement with Benitec Biopharma 12
ReNeuron Enters Into Co-Development Agreement With Cell Therapy Catapult 13
ReNeuron Enters into Licensing Agreement with US-Based Pharma Company 14
ReNeuron Raises USD105 Million in Private Placement of Shares 15
ReNeuron Raises USD25.4 Million in Private Placement of Shares 16
ReNeuron Group Completes Private Placement Of Shares For US$8.7 Million 17
ReNeuron Group Completes Rights Offering Of Shares For US$1 Million 19
ReNeuron Group Plc, Key Competitors 21
ReNeuron Group Plc, Key Employees 22
ReNeuron Group Plc, Subsidiaries 23
List of Figures
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ReNeuron Group Plc, Medical Devices Deals, 2012 to YTD 2018 10